Literature DB >> 6518938

Proliferative characteristics of primary and metastatic human solid tumors by DNA flow cytometry.

O S Frankfurt, W R Greco, H K Slocum, S G Arbuck, M Gamarra, Z P Pavelic, Y M Rustum.   

Abstract

The percentage of cells in S-phase (S-index) was calculated from DNA histograms of 453 primary and metastatic human solid tumors (predominantly bladder, breast, colorectal, renal, prostate, ovarian and lung carcinomas, melanomas, and sarcomas). S-indices varied widely among both primary and metastatic tumors (1-48%); there was no significant difference in S-indices between primary and metastatic tumors. The S-indices for aneuploid tumors were significantly higher than for diploid tumors. When data for all aneuploid tumors were analyzed collectively, there was no significant relationship between S-index and DNA ploidy index. However, for colorectal and ovarian carcinomas S-indices increased, and for lung carcinomas S-indices decreased with elevation in the degree of DNA-ploidy. Lung carcinomas had the highest S-indices. Comparison of flow cytometry (FCM) and cytology data indicated that for most diploid tumors S-indices reflect the proportion of S-phase cells among a mixed population of normal and tumor cells. For most aneuploid tumors, the proportion of tumor cells estimated cytologically was similar to the proportion of aneuploid cells estimated by FCM. For a small proportion of aneuploid tumors a comparison of cytology and FCM data indicated the presence of a predominant diploid tumor stemline and a minor stemline with aneuploid DNA content. There was a wide spread in the values of S-indices within tumor groups defined by degree of differentiation and stage of disease at surgery.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6518938     DOI: 10.1002/cyto.990050612

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  15 in total

1.  Cell proliferation in renal cell carcinoma--a comparative study of cell kinetic methods.

Authors:  P Larsson; G Roos; R Stenling; G D Wilson; B Ljungberg
Journal:  Urol Res       Date:  1996

Review 2.  Antibody Drug Conjugates: Preclinical Considerations.

Authors:  Gadi G Bornstein
Journal:  AAPS J       Date:  2015-02-28       Impact factor: 4.009

Review 3.  Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment.

Authors:  David Howard; Jetzabel Garcia-Parra; Gareth D Healey; Cynthia Amakiri; Lavinia Margarit; Lewis W Francis; Deyarina Gonzalez; R Steven Conlan
Journal:  Interface Focus       Date:  2016-12-06       Impact factor: 3.906

4.  Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma.

Authors:  S M Kheir; S D Bines; J H Vonroenn; S J Soong; M M Urist; J S Coon
Journal:  Ann Surg       Date:  1988-04       Impact factor: 12.969

5.  Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.

Authors:  Dongwei Gao; Sha Li
Journal:  Cancer Microenviron       Date:  2013-11-10

6.  The applications of the BrdUrd-technique for the estimation of cycling S-phase cells in human renal cell carcinoma.

Authors:  E M Langer; J Hemmer; G Kleinhans; W Göhde
Journal:  Urol Res       Date:  1988

7.  A case of inverted papilloma of the ureter: is the DNA ploidy pattern associated with occurrence of transitional cell carcinoma of the bladder?

Authors:  K Kunimi; T Uchibayashi; M Egawa
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

8.  Cellular DNA content and metastasis pattern in colorectal carcinomas.

Authors:  C Rübe; G Valet; M Eder
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

9.  Flow cytometric DNA histograms and type of growth.

Authors:  G Taubert; H Krug
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

10.  Prognostic importance of DNA flow cytometry in non-Hodgkin's lymphomas.

Authors:  J C Macartney; R S Camplejohn; J Alder; M G Stone; G Powell
Journal:  J Clin Pathol       Date:  1986-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.